Colorectal, Cancer Clinical Trials in Oklahoma City, Oklahoma

9 recruitingOklahoma City, Oklahoma

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Colorectal, CancerPancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal Adenocarcinoma+3 more
Revolution Medicines, Inc.1,130 enrolled32 locationsNCT06445062
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 4

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Colorectal, Cancer
Takeda78 enrolled45 locationsNCT06562543
Recruiting
Phase 1Phase 2

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Colorectal, CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.534 enrolled53 locationsNCT06128551
Recruiting
Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast CancerColorectal, CancerOvarian Cancer+6 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Liver CancerColorectal, CancerEndometrial Cancer+12 more
Elephas2,000 enrolled8 locationsNCT07327489
Recruiting

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Colorectal, Cancer
Tempus AI300 enrolled20 locationsNCT05234177
Recruiting
Phase 1Phase 2

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+5 more
Merus B.V.523 enrolled45 locationsNCT03526835
Recruiting
Phase 1

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Breast CancerColorectal, CancerPancreatic Cancer+2 more
Qurgen Inc.150 enrolled5 locationsNCT05989724